IL1B and psoriasis: Corroborating the notion, therapies targeting pyroptosis, such as IL-1β inhibitors, have shown moderate success in psoriasis, but the same treatments have had limited efficacy in HS, likely due to differences in the tissue-specific manifestation of inflammation [12].